chr11-58710008-C-G
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_201648.3(GLYAT):āc.649G>Cā(p.Val217Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000644 in 1,614,130 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.00031 ( 0 hom., cov: 32)
Exomes š: 0.000039 ( 0 hom. )
Consequence
GLYAT
NM_201648.3 missense
NM_201648.3 missense
Scores
1
8
10
Clinical Significance
Conservation
PhyloP100: 1.07
Genes affected
GLYAT (HGNC:13734): (glycine-N-acyltransferase) The glycine-N-acyltransferase protein conjugates glycine with acyl-CoA substrates in the mitochondria. The protein is thought to be important in the detoxification of endogenous and xenobiotic acyl-CoA's. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 0 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.15186319).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GLYAT | NM_201648.3 | c.649G>C | p.Val217Leu | missense_variant | 6/6 | ENST00000344743.8 | NP_964011.2 | |
GLYAT | XM_017017087.1 | c.457G>C | p.Val153Leu | missense_variant | 6/6 | XP_016872576.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GLYAT | ENST00000344743.8 | c.649G>C | p.Val217Leu | missense_variant | 6/6 | 1 | NM_201648.3 | ENSP00000340200.3 | ||
GLYAT | ENST00000529732.5 | c.649G>C | p.Val217Leu | missense_variant | 6/6 | 5 | ENSP00000431688.1 | |||
GLYAT | ENST00000611865.4 | c.649G>C | p.Val217Leu | missense_variant | 5/5 | 3 | ENSP00000484592.1 | |||
GLYAT | ENST00000586098.1 | c.88+2752G>C | intron_variant | 3 | ENSP00000468512.1 |
Frequencies
GnomAD3 genomes AF: 0.000309 AC: 47AN: 152230Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
47
AN:
152230
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000996 AC: 25AN: 251074Hom.: 0 AF XY: 0.0000958 AC XY: 13AN XY: 135698
GnomAD3 exomes
AF:
AC:
25
AN:
251074
Hom.:
AF XY:
AC XY:
13
AN XY:
135698
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000390 AC: 57AN: 1461782Hom.: 0 Cov.: 32 AF XY: 0.0000316 AC XY: 23AN XY: 727186
GnomAD4 exome
AF:
AC:
57
AN:
1461782
Hom.:
Cov.:
32
AF XY:
AC XY:
23
AN XY:
727186
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000309 AC: 47AN: 152348Hom.: 0 Cov.: 32 AF XY: 0.000309 AC XY: 23AN XY: 74494
GnomAD4 genome
AF:
AC:
47
AN:
152348
Hom.:
Cov.:
32
AF XY:
AC XY:
23
AN XY:
74494
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
4
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
18
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 21, 2021 | The c.649G>C (p.V217L) alteration is located in exon 6 (coding exon 5) of the GLYAT gene. This alteration results from a G to C substitution at nucleotide position 649, causing the valine (V) at amino acid position 217 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T;T;T
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Benign
D
LIST_S2
Benign
T;.;.
M_CAP
Benign
T
MetaRNN
Benign
T;T;T
MetaSVM
Benign
T
MutationAssessor
Pathogenic
M;M;M
PrimateAI
Benign
T
PROVEAN
Uncertain
.;N;N
REVEL
Uncertain
Sift
Uncertain
.;D;D
Sift4G
Uncertain
D;D;D
Polyphen
D;D;D
Vest4
MutPred
Gain of catalytic residue at V217 (P = 0.0609);Gain of catalytic residue at V217 (P = 0.0609);Gain of catalytic residue at V217 (P = 0.0609);
MVP
MPC
0.11
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at